Our Team
Our leadership team is composed of scientific and strategic professionals at the forefront of CNS research & development and commercialization, and is strengthened further by leaders in psychology, psychiatry, psychedelics, and oncology.
Management

Jan-Anders Karlsson, PhD
Interim CEO, Founder, Board Member

Anne C. Andorn, MD
Chief Medical Officer

Satish Prabhu, CPA
Chief Financial Officer

Åsa Holmgren, MSc Pharm
Head of Regulatory Affairs

Susan Learned, MD, PharmD, PhD
Head of Research & Development

Wilhelm Stahl, PhD
Head of CMC
Board of Directors

Philip Taub
Founder, Board Chair

Jan-Anders Karlsson, PhD
Interim CEO, Founder, Board Member

Lisa Deschamps
Board Member
Scientific Advisory Board

Gil Block, MD, PhD

William Breitbart, MD

Jim Grigsby, PhD

David Hellerstein, MD

Benjamin Kelmendi, MD
Strategic Advisory Board

John Andreadis

Mark Corrigan, MD

Stephen Juelsgaard, DVM, JD

Brad Sitko

Richard A. Yacenda

Reset Pharma has acquired an exclusive worldwide license from NYU Langone Health for intellectual property associated with the use of psilocybin and related psychedelics for the treatment of mental illness in patients with life-threatening diseases.
This agreement is based on the seminal work of Stephen Ross, MD, a world leader in advancing research on psychedelic medicine and a prominent psychiatrist with psycho-oncology expertise.
Reset Pharma is addressing demoralization syndrome in patients suffering from cancer
Sign up for our mailing list to learn more about our latest updates